Intravenous magnesium and inflammation after colorectal cancer surgery
Tests magnesium sulfate given during colorectal cancer surgery for effects on inflammation.
Plain-language title generated from the registry record
Registry title: Effect of Intravenous Magnesium on Postoperative Systemic Inflammatory Response in Patients Undergoing Colorectal Cancer Surgery
Key facts
- Where
- Cairo, EgyptSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 75 years old?
Source: NCT07803601, who can take part
Where in Egypt
- Ain Shams UniversityCairo, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ain Shams University
- Trial code
- NCT07803601
- Record updated
- 3 September 2026
- Original description
The aim of this study is to detect the effect of intraoperative intravenous magnesium sulfate on postoperative systemic inflammatory response by serum inflammatory parameters as CRP, WBCS and neutrophil count.Read full original descriptionShow less
Effect of Intravenous Magnesium on Postoperative Systemic Inflammatory Response in Patients Undergoing Colorectal Cancer Surgery
The aim of this study is to detect the effect of intraoperative intravenous magnesium sulfate on postoperative systemic inflammatory response by serum inflammatory parameters as CRP, WBCS and neutrophil count.
Inclusion: ASA I and ASA II; Age (35yrs - 75yrs); Patients undergoing open colorectal cancer surgery; Sex: Both sexes.
Exclusion: Previous / current immunomodulatory therapy; Renal impairment (Glomerular Filtration Rate < 60 ml\min); Allergy to study drug (MgSO4); Autoimmune disorders (eg: rheumatoid arthritis, multiple sclerosis and lupus), congenital and acquired immunodeficiency; Emergency condition (eg: obstruction or perforation in colorectal cancer); Postoperative complications altering inflammatory response (eg: infection, anastomotic leak); Cognitive impairment (eg: Dementia) and other psychiatric disorders by history; Severe cardiac dysfunction (Ejection fraction ≤ 30% or clinical signs and symptoms of reduced left ventricular ejection fraction), preoperative bradycardia (HR < 50 bpm) and atrioventricular block (first, second and third degree); Patient refusal to precipitate in this study; Duration of operation > 5 hours; Body mass index less than 18 or greater than 30 kg/m².